Gilead Sciences (GILD) Tops Q3 EPS by 38c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Gilead Sciences Announces Third Quarter 2023 Financial Results
November 7, 2023 4:02 PM ESTProduct Sales Excluding Veklury Increased 5% Year-Over-Year to $6.4 billion
Biktarvy Sales Increased 12% Year-Over-Year to $3.1 billion
Oncology Sales Increased 33% Year-Over-Year to $769 million
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2023.
Gilead has now delivered two years of consistent growth in our base business. In the third quarter, this continued growth was driven by both Virology and Oncology, said Daniel ODay, Gilead's Chairman and Chief Executive Officer. Our clinical... More
